#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Thrombotic microangiopathy Small intestine neuroendocrine tumour Wolfram syndrome Glioblastoma Facioscapulohumeral muscular dystrophy C3 glomerulopathy Erdheim-Chester disease Cardiac arrest Palmoplantar pustulosis Transitional cell cancer of the renal pelvis and ureter Primitive neuroectodermal tumour Cerebral arteriovenous malformation haemorrhagic Primary hyperoxaluria Neuromyelitis optica spectrum disorder Ataxia telangiectasia More trials…

    Learn about Rare Diseases

    Acquired haemophilia – Basic Information Short-bowel syndrome – Diagnostics Osteosarcoma metastatic – Diagnostics Gaucher’s disease type III – Life with Disease Biotinidase deficiency – Treatment Hereditary angioedema – Treatment Sarcoidosis – Life with Disease Burkitt’s lymphoma – Treatment Primary hyperoxaluria Vascular malformation – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Oleclumab Dicloxacillin Cilazapril Cx-037231 Nitrogen Casimersen Esflurbiprofen Dexibuprofen Roxithromycin Donepezil Hydrochloride Almagate Pozelimab Etoposide Phosphate Pegvaliase APAZUNERSEN Estradiol Etravirine Elenestinib Phosphate Radotinib Dihydrochloride Palonosetron More therapies…

    Learn about Your Condition

    Arterial disorder Spinal cord injury Gender dysphoria Chronic hepatitis B Petit mal epilepsy Endometrial cancer stage III Pigmentary glaucoma Splenic marginal zone lymphoma Stress urinary incontinence Neurodegenerative disorder Small intestine carcinoma Naevus flammeus Coronary artery bypass Periodontitis Benign prostatic hyperplasia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Non-Hodgkin’s lymphoma

  • Study of MK-1045 alone or with Tocilizumab in patients with Non‑Hodgkin Lymphoma to evaluate safety and efficacy

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Non-Hodgkin’s lymphoma
    Investigated Drugs:
    • Tocilizumab
    France Germany Italy Poland Spain

  • A Study of AZD4512 Alone or With Other Cancer Drugs for People With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

    Recruiting

    2 1 1
    Investigated Diseases:
    • Non-Hodgkin’s lymphoma
    Investigated Drugs:
    • AZD4512
    Italy

  • Study of TdT-3 cell therapy safety in patients aged 1 year and older with relapsed or refractory acute leukemia or lymphoblastic lymphoma

    Recruiting

    2 1 1
    Norway

  • Study on the Safety and Effects of Inobrodib, Betamethasone Sodium Phosphate, and Dimethyl Fumarate in Patients with Advanced Blood and Bone Marrow Cancers

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Myelodysplastic syndrome
    • Acute myeloid leukaemia
    • Non-Hodgkin’s lymphoma
    Investigated Drugs:
    • INOBRODIB
    • Teclistamab
    • Daratumumab
    Spain

  • Long-term Safety Study of AUTO4 and Rituximab in Patients with Potential Malignancy Treated with Autologous CAR T Cell Therapy

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Non-Hodgkin’s lymphoma
    • Systemic lupus erythematosus
    • Acute lymphocytic leukaemia
    Investigated Drugs:
    • Auto4
    • Autologous Enriched T Cells Retrovirally Transduced To Express Two Chimeric Antigen Receptors Targeting Cd19 And Cd22
    • Rituximab
    Spain

  • Study of EO2463, Lenalidomide, and Rituximab for Patients with Indolent Non-Hodgkin’s Lymphoma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Non-Hodgkin’s lymphoma
    Investigated Drugs:
    • Omp64
    • Omp65
    • Omp66
    France Italy Spain
1 2 3 4
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!